Adalta Ltd (1AD) - Total Liabilities

Latest as of December 2025: AU$2.07 Million AUD ≈ $1.46 Million USD

Based on the latest financial reports, Adalta Ltd (1AD) has total liabilities worth AU$2.07 Million AUD (≈ $1.46 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Adalta Ltd to see how much of total assets are deployed in long-term investments.

Adalta Ltd - Total Liabilities Trend (2012–2025)

This chart illustrates how Adalta Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Adalta Ltd asset portfolio.

Adalta Ltd Competitors by Total Liabilities

The table below lists competitors of Adalta Ltd ranked by their total liabilities.

Company Country Total Liabilities
Noronex Ltd
AU:NRX
Australia AU$1.04 Million
Oi S.A
SA:OIBR3
Brazil R$34.20 Billion
Adya Inc
V:ADYA
Canada CA$6.40 Million
JPMorgan Claverhouse Investment Trust Plc
LSE:JCH
UK GBX33.06 Million
HLT Global Bhd
KLSE:0188
Malaysia RM76.94 Million
Ecoslops SA
PA:ALESA
France €19.77 Million
GIGLIO.COM S.P.A. O.N.
F:5JR0
Germany €8.43 Million
Marvel Biosciences Corp
V:MRVL
Canada CA$4.33 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Adalta Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Adalta Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -9.46 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adalta Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adalta Ltd (2012–2025)

The table below shows the annual total liabilities of Adalta Ltd from 2012 to 2025.

Year Total Liabilities Change
2025-06-30 AU$2.74 Million
≈ $1.94 Million
-22.66%
2024-06-30 AU$3.54 Million
≈ $2.51 Million
-39.16%
2023-06-30 AU$5.82 Million
≈ $4.12 Million
+10.50%
2022-06-30 AU$5.27 Million
≈ $3.73 Million
+97.90%
2021-06-30 AU$2.66 Million
≈ $1.88 Million
-16.92%
2020-06-30 AU$3.21 Million
≈ $2.27 Million
+76.22%
2019-06-30 AU$1.82 Million
≈ $1.29 Million
+396.54%
2018-06-30 AU$366.32K
≈ $259.19K
+6.33%
2017-06-30 AU$344.51K
≈ $243.76K
+201.86%
2016-06-30 AU$114.13K
≈ $80.75K
-56.30%
2015-06-30 AU$261.18K
≈ $184.80K
-8.98%
2014-06-30 AU$286.95K
≈ $203.03K
-11.39%
2013-06-30 AU$323.83K
≈ $229.13K
+81.93%
2012-06-30 AU$178.00K
≈ $125.95K
--

About Adalta Ltd

AU:1AD Australia Biotechnology
Market Cap
$6.31 Million
AU$8.92 Million AUD
Market Cap Rank
#28213 Global
#1458 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more